Combined treatment with haloperidol and trazodone in patients with tic disorders

J Child Adolesc Psychopharmacol. 2000 Winter;10(4):307-10. doi: 10.1089/cap.2000.10.307.

Abstract

The combination of haloperidol and trazodone was evaluated in an open-label trial in 10 patients with chronic tic and Tourette's syndrome. We found a mean reduction of symptoms of 58.9% on the Yale Global Tic Severity Scale, with a statistically significant difference (p < 0.001) between the baseline and endpoint treatment conditions. This approach significantly reduces clinical symptoms, with the advantage of a lower dose of haloperidol than usual, with no side effects reported by the patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Antidepressive Agents, Second-Generation / administration & dosage
  • Antidepressive Agents, Second-Generation / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Child
  • Drug Therapy, Combination
  • Female
  • Haloperidol / administration & dosage
  • Haloperidol / adverse effects
  • Haloperidol / therapeutic use*
  • Humans
  • Male
  • Psychiatric Status Rating Scales
  • Tic Disorders / drug therapy*
  • Tic Disorders / psychology
  • Trazodone / administration & dosage
  • Trazodone / adverse effects
  • Trazodone / therapeutic use*

Substances

  • Antidepressive Agents, Second-Generation
  • Antipsychotic Agents
  • Haloperidol
  • Trazodone